Lege Artis Medicinae

[Shall we save?]

KIS János Tibor1

AUGUST 20, 2010

Lege Artis Medicinae - 2010;20(08)

AFFILIATIONS

  1. Budai Irgalmasrendi Kórház, Belgyógyászati Osztály

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Tracking the Forgotten Profession]

NAGY Zsuzsanna

Lege Artis Medicinae

[Friedrich Schiller – a Physician or a Poet Prince?]

BECHER Péter, PATAI Árpád, MÁJER Katalin

Lege Artis Medicinae

[An Endless Story?]

BÁNFALVI Attila

Lege Artis Medicinae

[Variations to the Kreutzer Sonata – Leo Tolstoy Passed Away 100 Years Ago]

KISS László

Lege Artis Medicinae

[Nasal Congestion as an Endemic]

NEMESI Zsuzsa

All articles in the issue

Related contents

Lege Artis Medicinae

[Pulmonary aspects of COVID-19 infection]

BÖCSKEI Renáta Marietta

[COVID-19 caused already the most serious pandemic of the past 100 years with increasing morbidity and mortality rates worldwide. Due to the aerosol-born virus, pneumonia develops in a significant part (ca. 20%) of patients with serious forms of acute respiratory distress syndrome (ARDS) ca. in 5-8% of all cases. For patients with chronic obstructive pulmonary disease, it is very important to save their well-controlled condition and to continue the maintenance therapy in co-morbid COVID-19 infection. The role of pulmonary exercises and rehabilitation is crucial. Thus, pulmonology outpatient clinics gained additional follow-up activities such as the long-term post-COVID care with complex functional assessments and regular structural imaging of discharged patients.]

Clinical Neuroscience

[Financing of medicines for treatment of rare diseases of the nervous system. orphan drugs in rare neurological diseases]

SZEGEDI Márta, KOSZTOLÁNYI György, BONCZ Imre, MOLNÁR Mária Judit

[Objectives – Nervous system involvement is expected up to 60-70% in case of rare diseases. This article aims to present the financial methods and expenditures of rare neurological diseases’ orphan medicinal products being financed in the frame of Hungarian social insurance system in 2012. Methods – The subsidized orphan medicines were selected on the Orphanet portal 2012 while orphans financed by compessionate use were provided by the Hungarian National Insurance Fund Administration (OEP) database. Three products exist without orphan designation, however those are intended for the treatment of rare neurological ailments. The medicines were categorized by financial methods and determined by costs. Results – Numerically, out of 36 pieces of subsidized orphan or orphan criteria fulfilled medicines 17 were authorized for the treatments of rare neurological diseases in the year of 2012. Most of the drugs (14 pieces) were to be financed in the frame of compassionate use by the reimbursement system. The cost amount of social insurance for 387 rare neurological disease patients reached more than 4.5 billion HUF (1.4% of the total pharmaceutical budget in outpatient care). Conclusions – In Hungary half of the subsidized orphans are intended for the treatments of rare neurological ailments. 30% of the total amount of social insurance for rare diseases’ medicinal treatments were used to subsidizing rare neurological disease patients in 2012. Most of the orphan medicines were to be financed in the frame of compassionate use by the reimbursement system for outpatient care. Consequently, a great deal of crucial problems occurred in relation with the unconventional subsidizing method. At the end of 2012 new financial methods have been elaborated and introduced in a pilot phase from 1 January 2013. In spite of the high cost commitment, nearly the entire diagnosed rare disease subpopulation have been provided with subsidized treatments in Hungary. In order to facilitate the acces to orphan medicines, collaboration shall be achieved by financing authority and professionals for identificating the descently sustainable, affordable and viable financial method. ]

Clinical Oncology

[Intersphincteric resection for low rectal tumors]

METZGER Péter

[The technical development of rectal surgery, together with chemo- and radiotherapy, improved the effi ciency of surgical intervention as well as the patients‘ survival and quality of life. The treatment of ultra deep malignancies - 2-3 cm from linea dentata - is a real challenge for rectal surgery. Before the introduction of laparoscopy the removal of the deep tumors with conventional surgical techniques was impossible to save the tumorous rectum. The new techniques made possible the ultra deep resection, i.e. the removal even those tumors which progressed until the linea dentata. The explosive use of laparoscopy and the new waves of chemo- and radiotherapy resulted signifi cance advance contributed to an interdisciplinary therapeutic approach, which is a well adapted method in deep rectal surgery. In case of ultra deep localization of tumors - 0.5-1.0 cm to linea dentata - the neoadjuvant therapy supported the saving the anal sphicter. This new techniques contributed to the preservation of feces continentia of the patient.]

Lege Artis Medicinae

[About stem cells]

PAPP Csaba

[Stem cells are special cells of an organism that are capable to continuously renew themselves and, triggered by environmental effects, to differentiate and produce cells suitable for various functions. Due to their special characteristics, stem cells have an exciting potential to fulfil an old dream of physicians: to replace and regenerate damaged cells and tissues. Regenerative medicine has undoubtedly opened new vistas in medicine and provides hope for those with yet uncurable diseases. Here, we briefly describe different kinds of stem cells and their sources and discuss some of their experimental or clinical applications. Besides the bone marrow, which is now considered a traditional stem cell source, we present alternative sources. Among these, we pay special attention to the two stemcell sources that are important for obstetricians and gynaecologists: the umbilical cord (Wharton’s jelly) and the characteristics of the umbilical cord blood. We discuss some aspects of the storage of cord blood (”stem cell banking“) its potential use. Obstetricians and gynaecologists have an important role and a great responsibility in promoting the collection and, if necessary, the use of these stem cells. Communicating with patients and informing them about the their possible therapeutic applications stem cells is a part of this process as well as obtaining cord blood and preserving a segment of the cord. Obstetricians and gynaecologists should help to save as much as possible the umbilical cord and cord blood, which become ”redundant“ after birth but are a great source of multipotent mesenchymal and haemopoietic stem cells, which can be used in various fields of 21st-century medicine.]

Hypertension and nephrology

[Prominents in Hungarian nephrology Professor Gyula Petrányi (1912-2000). Part II]

SZALAY László

[A nation can only survive and keep its identity through its traditions. This is why the initiative to launch this series coming from professor János Radó is worthy of attention. Gyula Petrányi is an outstanding personality in 20th century internal medicine, to be more precise in nephrology and immunology, his activity being wide-ranging. The first part of the current summary of his work deals with a tribute to his personality, and his role in immunomodularity treatment in glomerulonephritis. The second part shall cover his role in spreading renal biopsy, screening and caring kidney patients, dialysis, in developing kidney patients’ care, furthermore in clinicopharmacology and renal transplantation.]